Daiichi Sankyo’s Enhertu wins CHMP backing for EU adjuvant use in HER2-positive early breast cancer
AZN•DESTINY-Breast05 study results
DESTINY-Breast05 showed a 53% reduction in invasive disease recurrence or death versus T-DM1.
CHMP backs Enhertu for EU adjuvant use
EU drug regulator panel CHMP backed Enhertu for adjuvant use in HER2-positive early breast cancer with residual invasive disease.
Opinion supports decision on marketing authorization
The opinion supports Daiichi Sankyo and partner AstraZeneca ahead of a European Commission decision on marketing authorization.
